Objectives: To assess vertebral fracture (VFx) occurrence after percutaneous vertebroplasty (PVP) in patients with osteoporosis (OP), primary or secondary to chronic glucocorticoid (GC) therapy.
Methods: Prospective study of a 2-year follow-up.
Primary outcome: proportion of patients with new VFx 24 months after PVP. Eligible patients were osteoporotic patients with VFx and pain resistant to conventional therapy, under GC therapy (n=70) or not (n=71), who underwent PVP. X-rays of dorso/lumbar spine were performed before PVP and 12 and 24 months after the procedure. All the patients were given secondary fractures prevention with oral bisphosphonates plus calcium and vitamin D.
Results: The two groups were comparable with respect to male to female ratio, age, BMI, pain score, number of prevalent VFx and their score according to Genant, time interval between VFx and PVP, number of VFx that were treated, vitamin D and PTH plasma levels, and bone mineral density at femur sites. The proportion of patients with new VFx was higher at 12 and 24 months in the group taking GC; at 24 months was 44.3% in GC group and 22.6% in non-GC group (RR 1.96; 95% CI 1.19-3.26, p=0.0087). All new VFx were clinically evident. GC-treated patients had more falls than the patients who were not on GC: 43 falls per 100 pts/y and 32 falls per 100 pts/y, respectively (p<0.05); however, only 4 and 6 falls, respectively, caused a VFx (p=NS). Finally, logistic regression model showed that the increased risk of new VFx was associated with GC use (OR 4.53; 95% CI 1.50-13.69, p=0.0073) and low femoral neck T-scores (OR 3.57; 95% CI 1.82-7.02, p=0.0002).
Conclusions: Patients under treatment with GC show a two-fold increased risk of new VFx after PVP with respect to patients with primary OP. This should be weighed in the individual risk/benefit assessment of the procedure.